Biotechnology company Exicure Q3 net loss widens, existing cash not sufficient to continue to fund operations

Reuters
2025/11/08
Biotechnology company Exicure Q3 net loss widens, existing cash not sufficient to continue to fund operations

Overview

  • Exicure reports Q3 net loss of $2.4 mln, up from $1.1 mln last year

  • Company's cash position falls to $4.4 mln, as of September 30, 2025, from $12.5 mln at year-end 2024

  • Co believes that its existing cash and cash equivalents is not sufficient to continue to fund operations

  • Increased R&D and G&A expenses due to GPCR USA acquisition

Outlook

  • Company needs substantial additional financing to continue operations

Result Drivers

  • R&D EXPENSES - Increase in R&D expenses due to acquisition of GPCR USA

  • G&A EXPENSES - Slight rise in G&A expenses attributed to GPCR USA acquisition

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Net Income Before Tax

-$2.44 mln

Q3 Net Income

-$2.44 mln

Q3 Operating Expenses

$2.39 mln

Q3 Operating Income

-$2.39 mln

Press Release: ID:nGNX94GhK9

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10